HCU is an inherited disorder caused by the loss of function of cystathionine beta-synthase, which results in an excessive accumulation of homocysteine and its metabolites in the blood and urine. Patients develop multisystem clinical manifestations, including ectopia lentis, bone defects, intellectual disability, and life-threatening thromboembolisms, Synlogic said.

The experimental candidate, SYNB1353, is an engineered strain of the probiotic bacteria Escherichia coli Nissle (EcN), which consumes methionine in the gastrointestinal tract and prevents methionine absorption and conversion to homocysteine in plasma.

SYNB1353 was designed using Ginkgo's proprietary codebase. The high-throughput testing of codebase libraries by Ginkgo enabled SYNB1353 to advance from preclinical proof of concept to candidate strain in the space of a year, Synlogic said.

Ginkgo Bioworks to go public in SPAC deal worth over $1.6B
Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition...

Ginkgo reports revenue growth
Ginkgo Bioworks reported higher revenue for the first half of 2021, with new cell programs and collaborations fueling the company's growth, according...

Alternative gene therapies could be effective in treating some rare diseases
Bacteria-mediated genetic transfer has emerged as an alternative gene therapy (AGT) for the treatment of some rare diseases, such as phenylketonuria (PKU)....

Aldevron, Ginkgo Bioworks achieve mRNA manufacturing breakthrough

Aldevron and partner Ginkgo Bioworks said that their strategic partnership has led to a manufacturing breakthrough for an enzyme often used in manufacturing...

Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity...